Roche’s Ocrelizumab Found to be Superior to Standard Interferon Therapy in Relapsing Multiple Sclerosis Patients
Read about How Roche’s Ocrelizumab Found to be Superior to Standard Interferon Therapy in Relapsing Multiple Sclerosis Patients.
Continue Reading http://multiplesclerosisnewstoday.com
Join the Discussion